Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Huatai Securities is one of China’s largest and most prominent securities firms. It provides comprehensive financial services including wealth management, institutional brokerage and trading, investment banking, asset management, and international business. The company is publicly listed on the Shanghai Stock Exchange (601688), Hong Kong Stock Exchange (6886), and London Stock Exchange via GDRs (HTSC). It has a significant presence in both domestic Chinese markets and internationally through subsidiaries such as Huatai International in Hong Kong and AssetMark in the US[1][2][3][4][7].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Huatai Securities.